Category: misconduct investigations

Four retractions follow Swedish government findings of negligence, dishonesty

242915_1uu_logoA Swedish ethical review board has censured two biologists and their employer, Uppsala University, for events related to “extensive image manipulations” in five papers published between 2010 and 2014. The case has led to criticism from an outside expert — who brought the allegations to Uppsala — over the current system in Sweden for handling such investigations.

Four of the papers have been retracted, and the authors have requested a correction in the fifth.

After an eight-month investigation, in September the government-run Expert Group for Scientific Misconduct at the Central Ethical Review Board in Stockholm, Sweden, concluded that Uppsala professor Kenneth Söderhäll — who has published more than 200 papers — and lecturer Irene Söderhäll acted “negligently” and “dishonestly” by Continue reading Four retractions follow Swedish government findings of negligence, dishonesty

Nature retracts paper six years after it was flagged for fraud

cover_natureNature retracted a paper on protein structures today, six years after an investigation at the University of Alabama identified several structures that were “more likely than not falsified and/or fabricated” by one of the authors.

The paper came under scrutiny soon after it was published in 2006. A letter published in Nature that same year pointed out “physically implausible features in the structures it described.” That triggered the investigation at the University of Alabama, the result of which was published in 2009, identifying “nine publications related to the same protein structures that should be retracted from various scientific journals.” Everything was pinned on last author H.M. Krishna Murthy, who the investigation determined was “solely responsible for the fraudulent data.”

A 2009 Nature news article on the investigation declared that the “fraud is the largest ever in protein crystallography.”

We’re not sure what took Nature so long to retract the letter, titled “The structure of complement C3b provides insights into complement activation and regulation.” Here’s the note, which explains that not all the authors agreed to the retraction:

Continue reading Nature retracts paper six years after it was flagged for fraud

Third retraction appears for Leiden researcher fired in 2013

Screen Shot 2015-12-21 at 12.18.41 PM

A researcher who was fired from Leiden University Medical Center in 2013 for fraud has notched a third retraction, following an investigation by her former workplace.

When Leiden fired Annemie Schuerwegh, they announced two retractions of papers that contained manipulated data. This third retraction — the last, according to a spokesperson for the center  — is for “a discrepancy between the data reported in the article and the original collected data,” per the note.

The 2011 paper, “Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium” published in Arthritis Research & Therapy, suggests the source of a protein involved in rheumatoid arthritis. It has been cited 51 times, according to Thomson Scientific’s Web of Knowledge.

Here’s the retraction note:

Continue reading Third retraction appears for Leiden researcher fired in 2013

JAMA retracts osteoporosis paper with manipulated data

Screen Shot 2015-12-29 at 10.48.49 AMA JAMA study on an inexpensive treatment for osteoporosis has been retracted because the first author falsified or fabricated data. We’ve been expecting this one: An investigation at Women’s College Hospital in Toronto, the bone researcher’s former workplace, had already revealed issues with the paper.

An internal memo sent to staff (available in full here) in October explained that the investigation had found “unequivocal evidence of systematic data manipulation” by Sophie Jamal, who had already resigned from her positions at WCH and the University of Toronto.

The study appeared to show that nitroglycerin ointment could have a small positive effect on bone mineral density in postmenopausal patients. It’s been cited 30 times, according to Thomson Scientific’s web of Knowledge. (That’s two more times than when we last reported on the paper: It was cited once by the investigation, and once by a paper that was published earlier in October, but had not yet been indexed.)

Here’s the retraction note for “Effect of Nitroglycerin Ointment on Bone Density and Strength in Postmenopausal Women: A Randomized Trial:”

Continue reading JAMA retracts osteoporosis paper with manipulated data

Science flags immune-boosting paper under investigation

F1.mediumScience magazine has issued an expression of concern for a paper on the discovery of a new immune-boosting protein. The paper’s findings, which received some press coverage when they came out last spring, are now under investigation by Imperial College London.

The expression of concern follows a correction noting a Western blot mix-up. Science Editor in Chief Marcia McNutt told us last month that the mistake resulted from “carelessness” on the part of the authors. But now, an investigation at Imperial College London — where Philip Ashton-Rickardt led the research — is formally looking into the findings.

That investigation is ongoing, according to the expression of concern (signed by McNutt):

Continue reading Science flags immune-boosting paper under investigation

Authors retract abstract following misconduct by diabetes biotech

1Earlier this year, authors retracted a meeting abstract about a diabetes drug, following the revelation that the biotech that funded the trial committed misconduct.

The retraction was initiated by corresponding author Itamar Raz, at Hadassah Medical Center in Israel. The journal didn’t receive a response from any co-authors who were affiliated with the biotech company, Andromeda, so they were not included in the retraction process.

A few months after Hyperion Therapeutics acquired Andromeda’s diabetes drug DiaPep277, Hyperion announced it had evidence that some employees of Andromeda had “engaged in serious misconduct,” such as using un-blinded data and manipulating the analyses. Two relevant studies on the drug, designed to block the immune response that leads to type 1 diabetes, were retracted last year.

Here’s the retraction note for the abstract “Abstracts of the 50th Annual Meeting of the EASD, Vienna 2014. ‘Evaluation of DiaPep277® treatment in type 1 diabetes by integrated analysis,’” published in the May issue of the journal:

Continue reading Authors retract abstract following misconduct by diabetes biotech

Cancer researcher cleared of misconduct, inquiry finds “genuine error or honest oversight”

Khachigian
Levon Khachigian

An investigation at the University of New South Wales in Australia has determined that a long-accused cancer researcher did not commit misconduct.

The investigation did find instances when Levon Khachigian breached the code of conduct, but Continue reading Cancer researcher cleared of misconduct, inquiry finds “genuine error or honest oversight”

Singapore investigation leads to two retractions, two more on the way

cov150hAuthors have retracted papers from Cell Metabolism and the Journal of Biological Chemistry after an investigation in Singapore found issues, including falsified data. The investigation is ongoing, and two additional retractions, along with two corrections, are on the horizon.

The investigation looked into papers by first authors Sudarsanareddy Lokireddy, now a postdoc at Harvard, and Sandhya Sriram, a postdoc at the Agency for Science, Technology and Research in Singapore. Led by the Nanyang Technological University in Singapore, where some of the work was done, the investigation concluded that there were issues with six papers on which either Sriram or Lokireddy was first author.

All authors but Lokireddy have agreed to retractions or corrections. Ravi Kambadur of NTU, and Mridula Sharma at the National University of Singapore, are the last two authors on all the papers.

According to a notice from the NTU, the “investigation found a number of instances of alterations to data” in three papers on which Lokireddy is first author. One of those was retracted December 1 by Cell Metabolism: Continue reading Singapore investigation leads to two retractions, two more on the way

7th retraction for heart researcher who faked patient records

1.coverAnna Ahimastos, a heart researcher who faked patient records, has notched her 7th retraction.

One more paper is expected to be retracted, according to a spokesperson from her former institution, the Baker IDI Heart & Diabetes Institute in Australia.

As with the other retractions, the 2005 paper in Hypertension — about how the hypertension drug ramipril may help alleviate cardiovascular disease — is being pulled after Ahimastos admitted to scientific misconduct. She asserts the data remain valid, and has not signed the retraction notice.

The Hypertension paper has been cited 63 times, according to Thomson Scientific’s Web of Knowledge. Here’s the retraction note in full (the language will be familiar to readers who have been following this case):

Continue reading 7th retraction for heart researcher who faked patient records

Cancer researcher contributed “false data” to 11 studies

ori-logoA former cancer researcher has falsified data in 11 studies, according to the results of a investigation scheduled to be published in the Federal Register tomorrow.

The Office of Research Integrity’s findings are based on an inquiry at Virginia Commonwealth University, where Girija Dasmahapatra worked until July of this year, investigating possible therapies for cancer. The misconduct affected research funded by three grants from the National Institutes of Health. Steven Grant, a researcher at VCU, is the principal investigator on the grants, each of which total over $2 million in funding. All of the 11 affected papers will be corrected or retracted, according to the ORI notice.

Two of the papers containing “falsified and/or fabricated” data — a study on an experimental combination of drugs for blood cancer and one on chemotherapies for rare forms of lymphoma  — were covered in press releases by VCU.

According to the notice in the Federal Register:

Continue reading Cancer researcher contributed “false data” to 11 studies